Darunavir

Chemical formula: C₂₇H₃₇N₃O₇S  Molecular mass: 547.664 g/mol  PubChem compound: 213039

Therapeutic indications

Darunavir is indicated for:

Human immunodeficiency virus infection

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.

Darunavir be used to provide suitable dose regimens:

  • For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.
  • For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Darunavir is contraindicated in the following cases:

Colchicine in renal and/or hepatic impairment

Colchicine and additionally at least one of
Hepatic insufficiency
Renal failure

Severe hepatic impairment

Hepatic failure stage IV

Strong CYP3A inducers

at least one of
Strong potency CYP3A4 inducers
Cytochrome P-450 CYP3A5 strong inducers
Rifampicin
Hypericum perforatum (St John's Wort)
Lopinavir

Lopinavir/ritonavir

at least one of
Lopinavir and ritonavir
Lopinavir and additionally Ritonavir

Alfuzosin

Alfuzosin

Amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine

at least one of
Amiodarone
Bepridil
Dronedarone
Ivabradine
Quinidine
Ranolazine

Apixaban, rivaroxaban

at least one of
Apixaban
Rivaroxaban

Phenobarbital, phenytoin

at least one of
Phenobarbital
Phenytoin

Domperidone

Domperidone

Rifampicin, rifapentine

at least one of
Rifampicin
Rifapentine

Everolimus, irinotecan

at least one of
Everolimus
Irinotecan

Quetiapine

Quetiapine

Lurasidone, pimozide, sertindole

at least one of
Lurasidone
Pimozide
Sertindole

Elbasvir/grazoprevir

at least one of
Elbasvir and grazoprevir
Elbasvir and additionally Grazoprevir

Glecaprevir/pibrentasvir

at least one of
Glecaprevir and pibrentasvir
Glecaprevir and additionally Pibrentasvir

St John's wort (Hypericum perforatum)

Hypericum perforatum (St John's Wort)

Lovastatin, simvastatin

at least one of
Lovastatin
Simvastatin

Salmeterol

Salmeterol

Lomitapide

Lomitapide

Naloxegol

Naloxegol

Avanafil

Avanafil

Triazolam, oral midazolam

at least one of
Midazolam
Triazolam

Dapoxetine

Dapoxetine

Ticagrelor

Ticagrelor

Clopidogrel

Clopidogrel

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: DARUNAVIR KRKA 400 mg / 800 mg Film-coated tablet
Summary of Product Characteristics (SPC) 2023: DARUNAVIR KRKA 600 mg Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈